Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02006069 · ClinicalTrials.gov registry record · NA
MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing
A NA study, sponsored by Abbott Medical Devices.
- Terminated
- Registry status
- NA
- Development phase
- 5,850
- Enrollment target
NCT02006069: Clinical Trial NA study, sponsored by Abbott Medical Devices.
NCT02006069 is a NA study that was terminated before completion, run by Abbott Medical Devices. The registered enrollment target is 5,850 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (317% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02006069, a NA study, was terminated before completion, sponsored by Abbott Medical Devices.
- TERMINATED
- Registry status
- NA
- Development phase
- 5,850 participants
- Enrollment target
Study Summary
The purpose of this Clinical investigation is to assess the impact of the Multi Point Pacing (MPP) feature at 12 months in the treatment of patients not responding to standard Cardiac Resynchronization Therapy (CRT) after 6 months.
Primary Outcome
The primary endpoint of this study is evaluated at 12 months after enrollment and it is defined as the percentage of non-responder patients converted to responders after 6 months of MPP feature turned ON compared to baseline, as measured by Left Ventricular End Systolic Volume (LVESV) reduction of at least 15%.
Interventions
- DEVICE MPP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,850 participants |
| Start Date | 2013-12 |
| Est. Completion | 2021-05-30 |
| Phase | NA |
Why NCT02006069 stopped before completion
NCT02006069 is an interventional study that assigns participants to a tested intervention. Its 5,850 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (317% higher).
The record links to 0 conditions, and to 1 intervention - of which MPP is the first listed.
NCT02006069 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02006069 about?
NCT02006069 is a clinical study titled "MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing". The purpose of this Clinical investigation is to assess the impact of the Multi Point Pacing (MPP) feature at 12 months in the treatment of patients not responding to standard Cardiac Resynchronization Therapy (CRT) after 6 months.
What is the current status of trial NCT02006069?
This trial is currently terminated. It is a NA study. The enrollment target is 5,850 participants. The study started on 2013-12. Estimated completion is 2021-05-30.
What interventions are being tested in trial NCT02006069?
The interventions under investigation include: MPP (DEVICE).
Who is sponsoring clinical trial NCT02006069?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02006069's enrollment target sits among peer trials
5,850 24th of 2000 higher than 1,977 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03959085 · 5,951 participants · Phase 3
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- NCT06192511 · 5,980 participants · NA
Implementing a Novel Consent Process for Biospecimen Research After Newborn Screening
- NCT04983875 · 5,708 participants · NA
Mammography and Breast Arterial Calcification: An Information-Sharing Trial
- NCT00005095 · 6,000 participants
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia